Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Axsome Therapeutics Inc shares valued at $1,383,327 were purchased by Maizel Ari on Jan 21 ’26. At $184.44 per share, Maizel Ari acquired 7,500 shares.
Also, TABUTEAU HERRIOT sold 78,703 shares, netting a total of over 13,480,250 in proceeds. Following the sale of shares at $171.28 each, the insider now holds 7,229 shares.
Before that, TABUTEAU HERRIOT had sold 31,261 shares from its account. In a trade valued at $5,326,249, the Chief Executive Officer traded Axsome Therapeutics Inc shares for $170.38 each. Upon closing the transaction, the insider’s holdings decreased to 31,261 shares, worth approximately $1.37 million.
As published in a research note from Morgan Stanley on January 08, 2026, Axsome Therapeutics Inc [AXSM] has been rated down from an Overweight to an Equal-weight and the price target has been revised to $204. Analysts at B. Riley Securities started covering the stock with ‘”a Buy”‘ outlook in a report released in early October.
Analyzing AXSM Stock Performance
On last trading session, Axsome Therapeutics Inc [NASDAQ: AXSM] rose 2.49% to $189.1. The stock’s lowest price that day was $183.69, but it reached a high of $189.34 in the same session. During the last five days, there has been a surge of approximately 8.47%. Over the course of the year, Axsome Therapeutics Inc shares have jumped approximately 105.69%.
Is Axsome Therapeutics Inc subject to short interest?
Stocks of Axsome Therapeutics Inc saw a sharp steep in short interest on 2025-12-31 dropping by -0.68 million shares to 2.72 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 3.4 million shares. A decline of -25.0% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.49 of the overall float, the days-to-cover ratio (short ratio) decline to 4.49.
Which companies own the most shares of Axsome Therapeutics Inc (AXSM)?
In terms of Axsome Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 219 in the next 12 months, up nearly 18.7% from the previous closing price of $184.5. Analysts anticipate Axsome Therapeutics Inc stock to reach 260 by 2026, with the lowest price target being 193. In spite of this, 15 analysts ranked Axsome Therapeutics Inc stock as Buy at the end of 2026. On June 03, 2025, Oppenheimer assigned a price target of “an Outperform” to the stock and initiated coverage with a $185.
